UPPSALA, Sweden, Oct. 22, 2013 /CNW/ - Beactica today announced that it
has expanded its collaboration with Boehringer Ingelheim. For the
additional project, Beactica will use its proprietary fragment-based
platform to identify novel and selective hits against oncology-relevant
kinases of therapeutic interest to Boehringer Ingelheim. Financial
terms of the agreement were not disclosed.
(Logo: http://photos.prnewswire.com/prnh/20121029/572724 )
"We are pleased to expand our work with Boehringer Ingelheim and look
forward to further supporting them in their discovery of innovative,
new medicines for the treatment of cancer," said Beactica CEO, Dr Per
Källblad. "The collaboration builds on Beactica's strategy of
establishing long-term relationships with leading pharmaceutical
companies and validates the potential of our drug discovery platform."
Beactica's collaboration with Boehringer Ingelheim was established in
2008. Previous work under the collaboration includes the contribution
of important insights into the interaction mechanism of Giotrif®
(afatinib), a treatment that has been recently approved for lung cancer
patients with EGFR mutations in Europe and the US.
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the interactions of molecules in
order to generate novel and mechanistically defined therapeutics. The
Company offers expertise and services in the area of SPR
biosensor-based small molecule interaction analysis and partnerships
for fragment-based lead generation using its proprietary discovery
platform. Founded in 2006 based on research carried out at Uppsala
University and first-hand experience from the drug discovery industry,
Beactica has established a robust reputation as the leader in SPR
biosensor-based small molecule drug discovery. As well as providing
services and building collaborations with external companies, Beactica
is progressing its own drug discovery programmes.
For more information, please visit http://www.beactica.com/
The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 140 affiliates and more than 46,000 employees.
Since it was founded in 1885, the family-owned company has been
committed to researching, developing, manufacturing and marketing novel
medications of high therapeutic value for human and veterinary
Social responsibility is a central element of Boehringer Ingelheim's
culture. Involvement in social projects, caring for employees and their
families, and providing equal opportunities for all employees form the
foundation of the global operations. Mutual cooperation and respect, as
well as environmental protection and sustainability are intrinsic
factors in all of Boehringer Ingelheim's endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion
euro. R&D expenditure in the business area Prescription Medicines
corresponds to 22.5% of its net sales.
For more information, please visit: http://www.boehringer-ingelheim.com/
SOURCE: Beactica AB
For further information:
Media contact: For additional information please contact Dr Per Källblad, Beactica CEO, +46-18-56-08-80.